An interventional study of TROD (rapid diagnostic orientation test) and FibroScan® in Liver Pathology, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris — 4 open to participants now, 4 under way, none of them phase 3. Liver Cirrhosis · Assistance Publique - Hôpitaux de Paris.
Among the 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2025, is one of 5 with no phase, and was the 13th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →4 of the 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 242 across the 6 interventional studies, 226 across the 10 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
3 of the studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07439939Assistance Publique - Hôpitaux de ParisExploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement | 2027-06-09 |
| NCT06755632Assistance Publique - Hôpitaux de ParisScreening of Patients With Hepatic Fibrosis or Cirrhosis B and C | 2027-06-19 |
| NCT07028112Assistance Publique - Hôpitaux de ParisImpact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation. | 2027-08-20 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Regardless of its etiology (chronic hepatitis B or C, alcohol consumption, metabolic steatohepatitis, hemochromatosis, autoimmune liver disease), cirrhosis is a real public health issue. Cirrhosis is a chronic disease and can get complicated by liver cancer, digestive hemorrhage, or liver failure, which are responsible for morbidity and mortality.
In France, cirrhosis prevalence is estimated at 700,000 patients and induce 16,000 deaths per year (10,000 liver cancer and 6,000 liver decompensation). In Ile-de-France area, cirrhosis prevalence is estimated at 130,000 cases, a lot of them are in Seine Saint Denis department due to precariousness.
Hepatitis C virus can now be cured and hepatitis B treatment can suspend hepatitis B replication. All these treatments reduce liver complications but even after virological cure, cirrhosis requires dedicated long term management as well as alcoholic liver disease and metabolic steatohepatitis at cirrhosis stage.
Periodic screening for complications and specific measures were defined by french HAS in 2007 (medication intake, dietary management and specific vaccinations), especially the performance of a semi-annual liver ultrasound for hepatocellular carcinoma (HCC) screening.
Then, it seems essential to screen for patients with viral hepatitis and extensive fibrosis or cirrhosis in our department to achieve active and individualized management of this chronic liver disease, to reduce long term morbidity and mortality.
The main aim of the study is to evaluate the prevalence of advanced liver fibrosis and viral infections B and C in the general population of Seine Saint Denis, using a dual screening method of TROD (rapid diagnostic orientation test) and FibroScan®, combined with a care pathway
Targeted population
The targeted population will be users of one municipal health center visiting the municipal health center on a given day We will propose a screening for liver fibrosis using Fibroscan mini® and will propose rapid diagnostic orientation tests (TROD) for HCV and HBV viral infection, by a traveling physician Expérimental scheme
Proposal by the caregiver to each patient at the center :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic Test: TROD (rapid diagnostic orientation test) and FibroScan®
Fast-track appointment at the hepatology consultation at Avicenne Hospital (Bobigny) or the hepatology consultation at Jean Verdier Hospital (Bondy) for any patient : * with Fibroscan® ≥ 9.6 KPa or * positive hepatitis C serology or * HBsAg positive
Prevalence of significant hepatic fibrosis in the general population of Seine Saint Denis
Time frame: Two year of inclusion period
Chronic hepatitis B prevalence
Time frame: Two year of inclusion period
Chronic hepatitis C prevalence
Time frame: Two year of inclusion period
Proportion of eligible patients for management of viral hepatitis B and C
Proportion of eligible patients for management of viral hepatitis B and C
Time frame: Two year of inclusion period
Prevalence of other causes of chronic liver disease (alcohol and NASH)
Time frame: Two year of inclusion period
Proportion of patients managed in hepatology department after screening for significant fibrosis
Time frame: Two year of inclusion period
Prevalence of confirmed significant liver fibrosis in patients referred to hepatology consultation
This criterion will be assessed based on follow-up FibroScan results, non-invasive fibrosis blood tests, and/or liver biopsy when indicated, in accordance with current hepatology guidelines.
Time frame: Two years of inclusion period
Proportion of patients with ultrasound signs of cirrhosis and hepatocellular carcinoma among patients referred to hepatology consultation (managed according to current hepatology guidelines).
This criterion will be assessed based on abdominal ultrasound findings according to current hepatology guidelines.
Time frame: Two years of inclusion period
Not enrolling at this site.
Plan to share: No
Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.
Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 24 months is below that.
Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →